Advertisement
Advertisement

AIM

AIM logo

AIM ImmunoTech Inc

0.21
USD
-0.0005
-0.24%
Dec 18, 14:58 UTC -5
Closed
...

AIM ImmunoTech Inc Profile

About

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida.

Info & Links

CEO

Thomas K. Equels

Headquarters

2117 SW HIGHWAY 484
OCALA, FL 34473, UNITED STATES

Auditor

BDO USA, P.C

Share holders

150

Employees

28

AIM ImmunoTech Inc Statistics

Valuation Measures

Market Capitalization2

13.38M

Enterprise Value

15.20M

Enterprise Value/EBITDA(ttm)

-0.55

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

73.51

Price to Book(mrq)

4.79

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

80.67%

Operating Margin(ttm)

-12594.21%

Profit Margin(ttm)

-12033.40%

Return on Equity(ttm)

-421.73%

Return on Invested Capital(ttm)

-373.62%

Return on Assets(ttm)

-147.54%

Income Statement

Revenue(ttm)

190.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

154.00K

EBITDA(ttm)3

-27.40M

Net Income Available to Common(ttm)

-23.93M

Diluted EPS(ttm)

-0.47

Share Statistics

Beta (5Y Monthly)

-0.36

52-Week Change

-53.33%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

63.71M

Dividend Yield

0.00%

Float4

63.77M

% Held by Insiders

0.02%

% Held by Institutions

12.02%

Balance Sheet

Total Cash(mrq)

7.20M

Total Cash Per Share(mrq)

0.11

Total Debt(mrq)

2.73M

Total Debt/Equity(mrq)

93.82%

Current Ratio(mrq)

0.75%

Quick Ratio(mrq)

0.75%

Book Value Per Share(mrq)

0.05

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.19

Free Cash Flow(ytd)

-10.95M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement